China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement with US-based Incyte Pharmaceuticals Inc. (NSDQ: INCY), focusing on Incyte’s selective oral JAK1 inhibitor, povorcitinib. CMS has secured the exclusive rights to research, develop, file for regulatory approval, and commercialize the drug in Greater China, which includes mainland China, Hong Kong, Macao, and Taiwan, as well as in 11 Southeast Asian countries such as Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor Leste, and Brunei. Additionally, CMS has obtained non-exclusive manufacturing rights in these territories.
In exchange for these rights, CMS will pay Incyte an undisclosed upfront fee, with the commitment to additional potential milestone payments and net sales royalties. Povorcitinib is currently under development for the treatment of autoimmune and inflammatory skin diseases, including non-segmental vitiligo, purulent sweat gland inflammation (HS), nodular prurigo (PN), asthma, and chronic spontaneous urticaria.
This agreement follows a previous licensing deal in December 2022, where CMS obtained exclusive rights to Incyte’s Opzelura (ruxolitinib) in the same regions. Povorcitinib is currently undergoing Phase III studies for non-segmental vitiligo and HS, and Phase II studies for PN, asthma, and chronic spontaneous urticaria.- Flcube.com
